<?xml version="1.0" encoding="UTF-8"?>
<p id="p0120">Antibody binding of human plasma samples to the three antigenic site peptides (GP 469–498 at the C terminus of GP1, GP 520–547 in the fusion peptide, and GP 617–645 in the GP2-HR2 domain) that showed a strong correlation with neutralization titers possibly indicates an important role of antibodies to these sites in protection against EBOV infection and disease 
 <italic>in vivo</italic>. Although non-neutralizing antibodies may be protective 
 <italic>in vivo</italic>, preliminary data from recent clinical trial in the DRC have demonstrated that neutralizing antibodies like MAb 114 may provide better clinical outcome associated with significantly reduced mortality (
 <xref rid="bib21" ref-type="bibr">Kupferschmidt, 2019</xref>).
</p>
